Comparison of efficacy and safety between intraocular becacizumab and triamcinolone for diabetic macular edema

Chinese Journal of Experimental Ophthalmology

Volumn 29, Issue 6, 2011, Pages 559-563

  Wang, Li Li ^a   Zhang, Wen ^a   Li, Li Jie ^a   Jin, Li Ying ^a   Huo, Min ^a  

^a Xi'an Central Hospital   (China)

Author keywords

Becacizumab; Diabetes; Intraocular pressure; Intravitreal injection; Macular edema; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CENTRAL MACULAR THICKNESS; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA LIMBUS; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; THICKNESS; UNSPECIFIED SIDE EFFECT; VISION; VISUAL ACUITY; VITREOUS BODY;

EID: 84862082170     PISSN: 20950160     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.2095-0160.2011.06.017     Document Type: Article

References (13)

1. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema[J]. Ophthalmology, 2003, 110: 1690-1696.
2. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema[J]. Ophthalmology, 2005, 112: 806-816.
3. 2005, 23: 557-560.
4. 2008, 26: 708-712.
5. 2009, 27: 118-121.
6. la Cour M. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis[J]. Aeta Ophthalmol Scand, 2007, 85: 2-4.
7. Manzano R P, Peyman G A, Khan P, et al. Testing intravitreal toxicity of becacizumab(Avastin)[J]. Retina, 2006, 26: 257-261.
8. Beer P M, Bakri S J, Singh R J, et al. Intraocular concentration and pharmacokinetics of triamciolone acetonide after a single intravitreal injection[J]. Ophthalmology, 2003, 110: 681-685.
9. Leticia P, Rogerio A C, Marco S F, et al. Intravitreal triamciolone versus Bevacizumab for treatment of refractory diabetic macular edema. (IBEME Study)[J]. Br J Ophthalmol, 2007, 26: 1109-1122.
10. 2010, 28: 219-220.
11. Wai M C. Changes in aquenous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathalogic myopia[J]. Retina, 2008, 28: 1308-1313.
12. Shimura M, Nakazawa T, Yasuda K. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema[J]. Am J Ophthalmol, 2008, 145: 854-861.
13. Fung A E, Rosenfeld P J, Reichel E. The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide[J]. Br J Ophthalmol, 2006, 90: 1344-1349.